PepGen Inc. (PEPG)
1.26
-0.20 (-13.70%)
At close: Apr 03, 2025, 3:59 PM
1.25
-0.79%
After-hours: Apr 03, 2025, 04:59 PM EDT
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc.
| Country | United States |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Dr. James G. McArthur Ph.D. |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
| Website | https://www.pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| David E. Borah C.F.A., M.B.A. | Senior Vice President of IR & Corporate Communications |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member |
| Dr. Michelle L. Mellion M.D. | Chief Medical Officer |
| Emiko Bryant | Chief of Staff, HR & Operations |
| Kyle Breidenstine CPA, M.B.A. | Vice President of Finance & Controller |
| Mary Beth DeLena J.D. | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 3 | Filing |
| Mar 31, 2025 | 3 | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |